HTDK recently concluded a successful participation in the inaugural LSI Asia Summit, marking a significant step in its global business development strategy. As one of the world’s premier platforms for medtech innovation, LSI’s first Asia edition brought together international startups, industry leaders, and investors, fostering cross-border collaboration and accelerating the entry of global technologies into the Asian market.

HTDK CEO Teresa led the company’s delegation, actively engaging in multiple strategic dialogues centered on early-stage innovation screening, commercialization pathways, and localized partnership opportunities. This high-level presence not only reinforced HTDK’s reputation in the Asia-Pacific innovation ecosystem but also demonstrated the company’s strong execution in sourcing and cultivating high-potential global medtech projects.

During the summit, the BD team conducted multiple 1-on-1 meetings, roundtables, and pitch sessions with innovators from North America, Europe, Israel, and Asia-Pacific. Nearly 10 high-potential projects—spanning aesthetics, ophthalmology, COPD, cardiovascular, and peripheral nerve stimulation—have been shortlisted for further engagement, with post-summit follow-up already underway.

“Staying deeply involved in platforms like LSI is key to maintaining our innovation radar,” Teresa noted. “We’re not just seeking technology—we’re identifying ‘innovation seeds’ that resonate with China’s clinical needs and industrial resources. Whether you’re a startup or a market-ready company expanding into China, HTDK aims to be your most trusted local partner.”

HTDK remains committed to leveraging top-tier platforms such as LSI and MedTech World to access cutting-edge medtech innovation. With a structured and scalable global sourcing mechanism, HTDK continuously introduces feasible, high-quality medical technologies into the Chinese market—ensuring a sustainable and differentiated pipeline for domestic customers.

Each major global engagement is personally led by HTDK’s CEO, reflecting a strong commitment from top leadership. This approach strengthens front-end deal-making efficiency and enhances the team’s capabilities in project selection, and resource integration.

HTDK’s in-depth exchanges with international stakeholders during the summit have further solidified its credibility within the global medtech innovation ecosystem, laying the groundwork for future collaborations.

Building on the momentum from LSI Asia, HTDK will continue advancing follow-up opportunities via its end-to-end localization framework, covering cross-border evaluation, local production, clinical acceleration, and commercial deployment. Acting as a bridge between global innovation and China’s healthcare market, HTDK remains focused on delivering greater value for clients, partners, and investors.